| Name | Title | Contact Details |
|---|
Eniva Corporation is a Anoka, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discoveries to inspire the best life for every child and youth. The CHEO Research Institute is a not for profit corporation that connects exceptional talent and technology in pursuit of life-changing research for every child, youth and family in our community and beyond. We inspire trust in our research excellence by being curious, nimble, passionate and equitable.
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
RainDance Technologies, Inc. provides microdroplet-based solutions for single molecule and single cell analysis in the life sciences industry. The company’s RainStorm technology generates various discrete droplets that can encapsulate a single molecule, single cell, or reaction. It offers RDT 1000, a solution that amplifies genomic loci and leverages the sensitivity and specificity of polymerase chain reaction methodology; and ThunderStorm System, a fully automated high-throughput targeted sequencing solution that enables researchers to determine all variation contained in any region of the genome. The company also provides research screening panels, including ASDSeq for autism spectrum disorder research; XSeq for human X-chromosome research; and HLASeq for human leukocyte antigen and major histocompatibility complex research. In addition, it offers sequence enrichment consumables kits that comprise reagents and consumables, and custom-order libraries; and RainDrop Digital PCR System that transforms the performance of molecular assays by enabling digital answers across various applications, including tumor allele detection, gene expression, copy number variation, and SNP measurement. Further, the company provides remote and onsite response for various emergency repairs, including labor and travel, replacement parts and consumables, software revisions, and preventative maintenance. Its RainStorm technology serves various biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection. The company was founded in 2004 and is headquartered in Lexington, Massachusetts.
t+ Medical Americas is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.